Navigation Links
Michael J. Fox Foundation Announces $2 Million Funding Commitment to Drive Development of Parkinson's Disease Biomarker Pipeline
Date:5/7/2009

Initiative is one element of broader strategy to speed biomarkers progress

NEW YORK, May 7 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced a funding commitment of $2 million for Biomarkers 2009. This fourth round of biomarker funding by MJFF aims to continue stimulating discovery of new disease and drug biomarkers. At the same time, recognizing the critical need for an orchestrated, fieldwide strategy to drive tangible progress, MJFF is putting building blocks in place to launch a comprehensive biomarker discovery and verification effort in coming months.

"Lack of biomarkers is a major impediment to the development of disease-modifying treatments for Parkinson's disease, in large part because outcomes of clinical trials are extremely difficult to measure," said Katie Hood, CEO. "While considered a high-risk pursuit by many, The Michael J. Fox Foundation will continue to push biomarker research because development of PD biomarkers would be a major tipping point for the field, greatly accelerating the development of transformative new therapies."

The Foundation has been a field leader in the development of PD biomarkers for several years. Approximately $9 million in MJFF investment to date has resulted in the emergence of several lead biomarker candidates. Today's additional $2 million, directed toward biomarker discovery, underscores that commitment. Biomarkers 2009 will prioritize continued development of two separate types of biomarkers, both of major importance to PD therapeutics development: disease biomarkers and drug biomarkers.

Disease biomarkers are distinctive biological features or changes that are consistently different in people with PD than in people without PD. Identifying one or more disease biomarkers would allow researchers to diagnose earlier, track disease progression and identify appropriate subjects for clinical trials. Drug biomarkers are critical for objectively assessing whether a given drug is reaching brain areas of interest and/or achieving a desired effect.

Abbreviated information for applicants is below. Full details are available at www.michaeljfox.org/research.cfm.

Biomarkers 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Thursday, August 13, 2009

Funding Anticipated: November/December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.

    Media Contact:
    Holly Barkhymer
    (212) 509-0995 x242
    hbarkhymer@michaeljfox.org

    Research Contact:
    Mark Frasier, PhD
    (212) 509-0995 x244
    mfrasier@michaeljfox.org


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference
2. Aleres Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times
3. Dr. Michael B. Cates Takes Leadership Role on AVMAs One Health Joint Steering Committee
4. NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice
5. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
6. J. Michael Cook to Retire from Lilly Board of Directors
7. Michael J. Kussman, VA Under Secretary for Health, to Retire
8. Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards
9. Michael DeMane Joins Thomas, McNerney & Partners as Senior Advisor
10. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
11. HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... ... 2017 , ... The American Academy of Thermology ... and clinical application of medical infrared imaging, has announced two new educational offerings ... services. , The first new educational offering is an online self-directed Physician Member ...
(Date:5/22/2017)... NC (PRWEB) , ... May 22, 2017 , ... ... Matthews Periodontics, is now welcoming new patients with periodontal plastic surgery treatments, including ... from a general dentist. Dr. Green provides these esthetic and functional procedures to ...
(Date:5/22/2017)... ... ... An inventor from Columbia, S.C., wants to offer people with manual disabilities a ... firework accident, so she couldn’t grip a pen properly," he said. "This inspired me ... created a prototype for the HELPEN HAND, a special pen that enables a person ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less than ... when it was targeted to build a nuclear plant by the TOSHIBA Corporation. , ... Marvin L. Yoder describes the journey to get power to his small town, off ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... May 15, 2017 Enterin Inc., a privately-held CNS ... developing novel compounds to treat Parkinson,s disease (PD), has enrolled ... a Phase 1/2a randomized, controlled, multicenter study involving patients with ... enroll 50 patients over a 9-to-12-month period. The first stage ... patients with PD. Participating sites include Denver ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
Breaking Medicine Technology: